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The Min (multiple intestinal neoplasia) strain of the laboratory mouse and its derivatives permit the
fundamental study of factors that regulate the transition between normal and neoplastic growth. A gene
of central importance in mediating these alternative patterns of growth is Apc, the mouse homologue of the
human adenomatous polyposis coli (APC) gene. When adenomas form in the Min mouse, both copies of
the Apc gene must be inactivated. One copy is mutated by the nonsense Apc allele carried in heterozygous
form in this strain.The other copy can be silenced by any of several mechanisms.These range from loss of
the homologue bearing the wild-type Apc allele; to interstitial deletions surrounding the wild-type allele;
to intragenic mutation, including nonsense alleles; and ¢nally, to a reduction in expression of the locus,
perhaps owing to mutation in a regulatory locus. Each of these proposed mechanisms may constitute a
two-hit genetic process as initially posited by Knudson; however, apparently the two hits could involve
either a single locus or two loci. The kinetic order for the transition to adenoma may be still higher than
two, if polyclonal adenomas require stronger interactions than passive fusion.
The severity of the intestinal neoplastic phenotype of the Min mouse is strongly dependent upon loci
other than Apc. One of these, Mom1, has now been rigorously identi¢ed at the molecular level as encoding
an active resistance conferred by a secretory phospholipase. Mom1 acts locally within a crypt lineage, not
systemically. Within the crypt lineage, however, its action seems to be non-autonomous: when tumours
arise in Mom1 heterozygotes, the active resistance allele is maintained in the tumour (MOH or mainten-
ance of heterozygosity). Indeed, the secretory phospholipase is synthesized by post-mitotic Paneth cells, not
by the proliferative cells that presumably generate the tumour. An analysis of autonomy of modi¢er gene
action in chimeric mice deserves detailed attention both to the number of genetic factors for which an
animal is chimeric and to the clonal structure of the tissue in question.
Beyond Mom1, other loci can strongly modify the severity of the Min phenotype. An emergent challenge
is to ¢nd ways to identify the full set of genes that interact with the intestinal cancer predisposition of the
Min mouse strain.With such a set, one can then work, using contemporary mouse genetics, to identify the
molecular, cellular and organismal strategies that integrate their functions. Finally, with appropriately
phenotyped human families, one can investigate by a candidate approach which modifying factors
in£uence the epidemiology of human colon cancer. Even if a candidate modi¢er does not explain any of
the genetic epidemiology of colon cancer in human populations, modi¢er activities discovered by mouse
genetics provide candidates for chemopreventive and/or therapeutic modalities in the human.
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1. INTRODUCTION
As a dynamically self-renewing tissue, the intestinal
epithelium must maintain homeostasis by possessing both
positive regulators driving cell proliferation and negative
regulators mediating cell loss. The complexity of homeo-
static regulation can be inferred from the fact that
neoplasms of the intestinal epithelium, although among
the most common of human cancers (Cutler et al. 1974),
do not a¥ict every individual in spite of the risk attendant
to vast numbers of mitotic events per day within the intest-
inal epithelium. Indeed, the age dependence for the onset
of clinically diagnosed colon cancer has been modelled
mathematically as re£ecting a six-hit process (Peto et al.
1975).
Descriptive analysis introduces members of the
molecular and cellular casts of characters found in three
biological dramas: normal, self-renewing growth;
neoplastic growth; and regenerative growth after damage
from ionizing radiation. Some of these characters can be
shown to act as causative protagonists or antagonists
within one or more of these dramas. A causative role is
inferred by the discovery of a mutation a¡ecting the
molecular or cellular character and simultaneously
a¡ecting the biological process. The genes for which such
mutational evidence has been available involve human
Phil.T rans. R. Soc. Lond. B (1998) 353, 915^923 915 & 1998 The Royal Societyfamilies with strong predispositions to cancer. These
highly penetrant, dominant mutations have enabled the
molecular cloning of the causative molecules by analysis
of DNA samples from a¡ected and una¡ected members of
these families. However, the full dramas of normal self-
renewing growth and its deranged neoplastic counterpart
involve far more than the highly penetrant protagonists
and antagonists. How can investigators identify more
fully the set of molecular and cellular interactions that
can in£uence the outcome of the play? And once any one
interaction has been identi¢ed on an abstract, formal
basis, how can one analyse its mechanics?
These questions can best be addressed in an experi-
mental organism, preferably a mammal. The laboratory
mouse has been highly developed for controlled studies of
cancer genetics and cancer biology. The production of
genetic models for familial human cancers has not been
routinely successful (Jacks 1996). However, the Min
(multiple intestinal neoplasia) mouse strain, heterozygous
for a nonsense mutation in the mouse adenomatous poly-
posis coli (Apc) gene (Su et al. 1992), does show at least the
early stages of the familial cancer syndrome (Moser et al.
1990). A number of investigators are studying how well
the Min mouse can provide an experimental stage on
which to identify functional interactions in the normal
and neoplastic growth of the intestinal epithelium (see
Dove et al. 1995; Shoemaker et al. 1997a). The biology and
genetics of the laboratory mouse is used in these studies to
analyse in vivo the mechanism of interaction, through clas-
sical genetic pathway analysis and several modes of
chimerism and mosaicism. It remains tobe seen how accu-
rately these in vivo analyses can be carried over to in vitro
culture.
The ¢nal goal of the investigators working with the Min
mouse strain is to determine whether mechanisms found to
be important for the intestinal epithelium and its
neoplasms in the laboratory mouse are also relevant to
the human. No one presumes identity either in the
biology or the genetic epidemiology between the mouse
and the human species. But all must respect the depth of
understanding that can be created by controlled experi-
mentation. Given this starting point, it is necessary to
make an appropriate interspecies translation from mouse
to human.
2. THE CENTRALITY OF THE Apc REGULATOR
It is useful to view the`tumour suppressor gene' Apc as a
regulator rather than an engine of cell behaviour: tumour
cells and trophoblastic giant cells within embryos (Moser
et al. 1995) can thrive in the absence of Apc function.
Several cell processes are known to be directly or indir-
ectly regulated by Apc. These include transcription,
adherens junction formation, the microtubular cyto-
skeleton, calcium-dependent cell adhesion, and cell
migration (see Polakis 1995).
As expected for a negative regulator, intestinal tumour
formation commonly requires the loss of function of both
alleles at the Apc locus (Knudson 1971; Luongo et al. 1994)
(¢gure 1). For the ApcMin/+ mouse on the tumour-sensitive
C57BL/6 genetic background, this process is completed by
loss of the chromosome carrying the wild-type Apc allele.
Interstitialdeletionsinducedbysomaticgammairradiation
delimit the necessary region of genetic loss to theApc locus
(Luongo& Dove1996). Somatictreatment with ethylnitro-
sourea (ENU) induces point mutations in Apc, most
frequently detected as chain terminations of the Apc poly-
peptide (Shoemakeretal.1997b).
When the Min mutation is placed on the highly tumour-
resistant AKR genetic background, the chromosomal loss
pathway for removing wild-type Apc function is less
prevalent (A. R. Shoemaker, unpublished data). Interest-
ingly, F1 hybrids between the sensitive C57BL/6 strain
and the resistant AKR strain show the chromosomal Apc-
loss pattern of C57BL/6 (Luongo et al. 1994; Luongo &
Dove 1996). This observation is consistent with dominant
determination of chromosomal instability by an allele or
alleles carried by C57BL/6 (see Lengauer et al. 1997).
Evidence for germline factors in£uencing karyotypic
stability has now been published (Cahill et al.1998).
When the chromosome loss pathway is less frequent, as
with strain AKRMin, a new scenario comes to light
(¢gure 2). Tumours form at very low multiplicity, owing
not only to the attenuation of the chromosome loss
pathway but also to the action of resistance alleles of poly-
morphic modi¢er loci such as Mom1 (to be discussed
below). When tumours form while retaining the chromo-
some carrying the wild-type Apc allele, the expression of
the Apc polypeptide is attenuated (¢gure 3). This loss of
expression is not accompanied by any known mutation of
the Apc gene: the wild-type DNA sequence at the Min site
is retained, and no chain-terminating mutations of Apc are
detected (A. R. Shoemaker, unpublished data). This
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Figure 1. Adenoma formation in ApcMin/+ mice. Under sensi-
tive conditions of genetic background and/or exposure of
animals to ethylnitrosourea (ENU), adenomas form by a
canonical Knudson (1971) process involving genetic inactiva-
tion of both alleles at the Apc locus.
Figure 2. Adenoma formation in ApcMin/+ mice on the resistant
genetic background of AKR. When the canonical Knudson
(1971) process (¢gure 1) is less probable, a distinct route for
silencing the wild-type Apc allele can be inferred (see text).scenario is currently mysterious, with several conceivable
explanations: (i) the wild-type allele might be silenced by
a stable epigenetic change, along lines initially suggested
by Solomon, Bodmer and their colleagues (Solomon et al.
1987); (ii) a speci¢c epigenetic mechanism, hypermethyla-
tion of the Apc promoter, might attenuate Apc expression
(Hiltunen et al.1997); or (iii) a second locus that regulates
the expression of Apc might be somatically mutated
(Haber et al. 1990). Consistent with this last possibility,
the incidence of tumours retaining but not expressing an
apparently normal Apc allele is increased by appropriately
timed ENU treatment of AKRMin mice (A. R. Shoe-
maker, unpublished data).
Note that adenoma formation by this alternative
pathway remains dependent on the germline ApcMin allele:
no intestinal adenomas have been found in control AKR
animals. Evidently, the mechanism of attenuation,
whether purely epigenetic (model (i) or (ii)) or down-
stream of a regulatory mutation (model (iii)), is not
su¤ciently strong to silence successfully both wild-type
copies of Apc in an Apc+/+ animal.
The presentation of an alternative molecular genetic
route to Min-dependent adenoma formation in strain
AKR raises the possibility that there can be more than
one stem cell origin for such tumours. The study of this
possibility would be greatly enhanced if a rich set of diag-
nostic molecular markers became available for the stem
cells of the intestinal epithelium and its neoplasms. At
present, only the lacZ insertion ROSA11 provides such a
marker (Gould & Dove 1996).
Altogether, one feature is shared by the several speci¢c
mechanisms of adenoma formation in the Min mouse:
Apc function must be strongly reduced or lost. This
function must play a central role in protecting the normal
intestinal epithelium against the dysplastic and neoplastic
derangements that lead to adenoma and beyond. A central
protective function such as this has been designated a
`gatekeeper' by Kinzler & Vogelstein (1996). If Apc acts as
a `gatekeeper', is loss of its function su¤cient to generate
the intestinal adenoma?
The issue of su¤ciency is being pursued along three
lines of inquiry: the search for developmental stages at
which adenoma formation is enhanced; the analysis of
cellular interactions between Apc-negative clones in
adenoma formation; and the identi¢cation of loci other
than Apc in which mutations enhance or suppress the prob-
ability of Min-induced adenoma formation. The develop-
mental pro¢le for adenoma formation was studied by
timed somatic treatment of Min mice with ENU. It was
found that neonates up to 14 days of age were particularly
susceptible to stimulation of adenoma formation (Shoe-
maker et al.1995).
3. THE POLYCLONAL STRUCTURE OF EARLY
ADENOMAS IN Min MICE
The number of genetic events involved in tumorigen-
esis is increased if tumours are polyclonal (Novelli et al.
1996). Whether this increase is obligatory depends upon
whether the polyclonality is necessary. This issue requires
deeper experimental study and has been started by
analysing the clonal structure of early adenomas in the
Min mouse (Merritt et al. 1997). The analysis has
employed a cell lineage marker, ROSA26, that expresses
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Figure 3. Silencing of Apc+ expression. Antibody 3122 to Apc (Midgley et al. 1997) was used for the detection of wild-type Apc
antigen by immunoperoxidase (A. R. Shoemaker and C. Midgley, unpublished data). Normal crypts display abundant antigen,
but adenomatous tissue is negative in tumours that form in AKRMin animals after neonatal exposure to ENU.the b-galactosidase of E. coli in all cell types of the intest-
inal epithelium or its neoplasms (Wong et al. 1996;
Zambrowicz et al. 1997; Gould & Dove 1997). Whole-
mount tissue stained with the substrate X-Gal can be
visualized as blue before or after sectioning. T o avoid
complications of genetic modi¢ers of the tumour pheno-
type, ROSA26 was introgressed onto the standard
sensitive genetic background, C57BL/6. Perhaps owing
to the isogenicity of the two components of the aggrega-
tion chimeras, the intestinal epithelium shows very ¢ne-
grained chimerism for the two participating genetic
lineages (¢gure 4). The average patch diameter is only
six crypts. By fusion of morulae emerging from appro-
priate crosses, two informative chimeric animals were
generated, each with the composition
ROSA26/+ Min/+ $ +/+ Min/+.
Analysing tumours from these chimeras, Ch112 and Ch113,
established that both the white and blue components
carried the Min allele.
Eachchimerawasasymmetric,withaminorityROSA26/
+ (blue) component.Thebestestimatorof the proportionof
adenomasthatarepolyclonalinstructurecanbemadefrom
this minority component, as the probability that a
polyclonaltumour willbe covert (blueblue) is small. Of a
totalof 260 adenomas fromthe entire intestinaltracts of the
twoinformativechimeras,28 adenomaswere observedwith
at least some blue contribution. Of these, 22 were mixed
withwhitetumourtissue.Thus,theproportionofpolyclonal
adenomas canbe estimatedtobe at least 79%.
These observations are consistent with the study of poly-
clonality in a human familial adenomatous polyposis
(FAP) patient reported by Novelli et al. (1996). Impor-
tantly, the chimeric analysis that is permitted by the
ROSA26 cell lineage marker is not open to the alternative
interpretation o¡ered by Novelli and his colleagues for
their material: that the mixed XY/XO karyotype of the
human FAP adenomas had been created after the initia-
tion of the tumour by loss of the dicentric Ychromosome
within the tumour. However, neither set of observations
demonstrates that the adenoma is polyclonal when ¢rst
formed. Alternative models will be discussed below,
wherein the polyclonality is acquired, not de novo.
Bjerknes et al. (1997) have reported adenomas in FAP
patients in which only a subset of the dysplastic crypts
have lost the expression of APC. Do these phenotypically
mixed FAP human adenomas correspond to the polyclonal
Min mouse adenomas documented by lineage marking?
Gould & Dove (1997) observed that adenomas in chimeric
mice in which one component was Apc+/+ were derived
only from the Min/+ component. In microdissected blue
and white sectors of mixed adenomas from Ch112 and
Ch113, the Apc genotype has been analysed. In most cases,
each sector is ApcMin/0 (Merritt et al.1997).
Remarkably, at least two rare somatic events have
contributed to the polyclonal adenoma, in distinction to
the observation of assimilative dysplasia by Bjerknes et al.
(1997). How can one understand the coincident occurrence
of at least two somatic non-disjunction events within a few
crypt diameters of one another? Perhaps the events are not
independent. Can mitotic non-disjunction be induced by a
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Figure 4. Chimerism for ROSA26 (lacZ). Whole-mount colonic tissue from a morula fusion chimera C57BL/6 $ C57BL/6ROSA26/+
was histochemically stained by XGal. Control non-chimeric ROSA26/+ animals display uniform staining in all cell types of the
intestinal epithelium. Negative controls (C57BL/6) show no staining.neighbouring Apc-negative clone? Do clastogenic `storms'
pass over the developing gut? As noted above, the
neonatal crypt seems to be a favoured precursor for the
adenoma; neonatal crypts have an intrinsic polyclonal
architecture (Schmidt et al.1988).
The polyclonal structure of most, if not all, early
familial adenomas can re£ect any of a broad range of
mechanisms for clonal interaction. Strong interaction
models posit that cellular interactions are necessary for
the initiation of adenomas (¢gure 5). These models
resemble the formalism of the `community e¡ect' in deter-
minative changes of embryonic potential (Gardner 1993;
Gurdon et al. 1993), or polyclonal transdetermination
within imaginal disks of Drosophila (Gehring 1967), but
require that the cooperating cells be Apc-negative somatic
variants. Intermediate models involve quantitative rather
than qualitative requirements for cellular interaction. For
example, the ability of a nascent adenoma to grow to
detectable size or to survive any purging process of the
host may be enhanced by fusion with a neighbouring
adenoma. Finally, passive interaction models propose that
only a limited region within the intestinal epithelium of an
animal can develop adenomas, enhancing the probability
of fusion (see Novelli et al. 1996, footnote 25). A simple
mathematical representation of the spatially random
fusion model posits that pre-adenomas form by a homoge-
neous Poisson process and fuse if they are su¤ciently close
(M. A. Newton, unpublished data). Approximations
derived from this model lead to a likelihood function for
a parameter governing the expected number of preade-
nomas in a particular region, involving only the counts of
pure and mixed tumours. Linking this information with
the dimensions of the intestinal regions, it is calculated
that the mixed tumour counts in the small intestine of
chimeras Ch112 and Ch113 do not rule out random
fusion. However, for the colons of these two chimeric Min
mice, the fusion model would require a spatial restriction
of colonic adenomas to 20% of the available tissue. It
remains unstated what biological factor would spatially
restrict adenoma formation in this passive model.
Depending upon the strength of the clonal interaction
that explains the polyclonal structures of most, if not all,
familial intestinal adenomas, we must re-evaluate the
process of sporadic cancer in this tissue. If adenoma
formation absolutely requires cooperation between a pair
of initiated clones, then two initiation hits are required in
the familial and four in the sporadic case (cf. Knudson
1971). In this cooperation model, it seems plausible that
promoting agents would provide the necessary community
of initiated cells within a single lineage through formation
of an initiated microclone (Rous & Kidd 1941). Indeed,
Ponder & Wilkinson (1986) and Gri¤ths et al. (1989)
have provided strong evidence for monoclonality in
chemically induced intestinal tumours in mice. The latter
report is particularly persuasive in that very small patch
sizes were achieved, owing to the isogenicity a¡orded by
X-inactivation mosaicism. Covert polyclonality would be
rare in these experiments.
Daunting experimental challenges now emerge: to
determine the nature and strength of the cellular interac-
tions that explain the polyclonal structure of early familial
adenomas; and to extrapolate an understanding from the
familial case to the far more prevalent sporadic case.
Because chemical carcinogenesis may involve tissue
damage and regeneration, we cannot reliably equate that
process to sporadic neoplasia.
4. MODIFIERS OF THE MIN PHENOTYPE
A number of molecules are already known to interact
directly with the APC/Apc polypeptide, and a number of
molecular species are known to be induced in intestinal
adenomas. In principle, mutations that modify the Min
phenotype can occur in molecules that interact with
APC/Apc either directly or indirectly. The search for
these interactors began with the ¢nding that F1 hybrids
generated by mating the sensitive B6-Min strain to
certain other inbred mouse strains show tumour multipli-
cities reduced by up to an order of magnitude (Moseret al.
1992). By synergizing with the emergent dense genetic
map of the mouse organized in the Genome Center at the
Massachusetts Institute of T echnology (MIT), it was
possible to map a polymorphic modifying locus, Mom1
(modi¢er of Min), to a 15-centimorgan (cM) interval on
mouse chromosome 4 (Dietrich et al.1993).T o study Mom1
in the absence of other polymorphic modi¢er alleles
carried by Min-resistant inbred strains, a congenic deriva-
tive of C57BL/6 was established, heterozygous for a 30-
cM region containing the resistance allele of strain AKR
(Gould et al.1996a).
With this `puri¢ed' genetic material, it was possible to
obtain contemporaneous parallel sets of progeny each
carrying the ApcMin allele but di¡ering in the Mom1 region.
The alleles at the Mom1locus control the net growth rate of
Min-induced adenomas semidominantly. T umour multipli-
city also shows a semidominant response to the alleles of
Mom1.The semidominance prevented knowing which Mom1
allele is active: resistance, sensitivity, or both.
A further re¢nement of the map location of Mom1 was
carried out by identifying animals carrying chromosomes
recombinant within the 30-cM congenic substitution and
then phenotyping a set of testcross progeny carrying the
recombinant chromosome.This demanding process delim-
ited the Mom1locus to a 3-cM interval (Gould et al.1996b).
It is almost prohibitive to identify at molecular resolu-
tion a locus whose phenotype is only quantitative
(Falconer & Mackay1996). Recombinants must be pheno-
typed by establishing populations of animals. The
di¤culty is compounded for polymorphic determinants,
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Figure 5. Is polyclonality of intestinal adenomas necessary?
The extreme model is presented in which the formation or
survival of adenomas requires clonal cooperation (`polyclonal
origin').owing to the background level of polymorphic nucleotide
substitution of at least one substitution per 1000 base pairs
(see Dove 1987). One can, however, explicitly test candi-
date genes that map within the 3-cM region to which the
quantitative determinant can be feasibly mapped. One
candidate, a secretory phospholipase (encoded by
Pla2g2a), was suggested by MacPhee et al. (1995), survived
the 3-cM delimitation process (Gould et al. 1996b), and
therefore deserved an explicit test. A cosmid transgene
carrying the entire genomic sequence for Pla2g2a was
isolated by our collaborators Karen Hong and Eric
Lander (MIT) and transferred into B6-Min mice
(Cormieret al.1997).Westernblots and immunohistochem-
istry for the secretory phospholipase indicated that the
transgene was expressed throughout the small and large
intestine, although the levels were much higher and the
distribution more patchy in comparison with the antigen
encoded by the AKR allele of Mom1.
The transgene confers a twofold reduction in tumour
multiplicity on B6-Min mice, establishing that the secre-
tory phospholipase can provide for active resistance
(Cormieret al.1997). It is premature, however, to conclude
that Pla2g2a accounts fully for Mom1. The transgene,
although overexpressed, does not achieve the same level
of resistance as found with two copies of the AKR allele
of Mom1. Furthermore, the ¢ne-structure analysis of
Gould et al. (1996b) indicated that the Mom1 locus could
be subdivided into more than one factor. The full story of
the e¡ects of Mom1on the net growth rate and multiplicity
of Min-induced intestinal adenomas remains to be learned.
If the e¡ect of Mom1involves active resistance mediated
by a secretory phospholipase, does it act as a cell-autono-
mous negative regulator of the intestinal adenoma, that is,
as a classical`tumour suppressor gene'?
Two tests for cell-autonomous action of the resistance
allele of Mom1 have been carried out: chimeras generated
by grafting foetal intestine from Mom1-sensitive donors to
Mom1-resistant hosts (Gould & Dove 1996); and chimeras
generated by morula fusion, in which the Mom1-resistance
allele is introduced either in the same lineage as the Min
mutation, or in a separate lineage (Gould & Dove 1997).
In each case, the Min phenotype matched that of the
ApcMin/+ component of the chimera; no e¡ect of the
Mom1-resistance allele could be detected when that allele
was carried by the Apc wild-type component of the
chimera. Note that this test for cell autonomy cannot
detect intercellular action between di¡erent cells lying
within the same crypt lineage. Because the adult crypt is
monoclonal, all its derivatives belong to the same lineage.
The secretory phospholipase seems to be expressed at least
in the Paneth cell compartment of the small intestinal
crypts and could di¡use from that source to a¡ect the
behaviour of proliferative cells within the same crypt.
Two strategic points need to be recognized in these
chimeric analyses of cell-autonomous versus intercellular
gene action. First, the interpretation of these experiments
becomes ambiguous if the components of the chimera
di¡er by more than one gene a¡ecting the phenotype. In
plausible situations, autonomy for one factor will obscure
non-autonomy for a second (¢gure 6).
For example, consider an autonomous positive regulator,
A, and a di¡usible positive regulator, D. If the active wild-
type alleles of both A and D lie in one component of a
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Figure 6. Tests by chimerism for autonomy of gene action.
Ambiguity of interpretation arises if more than one genetic
factor controlling the phenotype di¡ers between the two
components of a chimera (see text).chimera and the inactive mutant alleles in the other, the
autonomy of A will prevail if both A and D are necessary
or if D operates by activating A. By contrast, if A operates
by activating D, then the non-autonomy of D will prevail.
A second strategic consideration, raised above in respect
to the Paneth cell, indicates that the resolution to which cell
autonomycanbe assessed depends uponthe clonal architec-
ture of the tissue in question. In an extreme situation in
which an entire tissue emerges from one somatic clone, one
clearly cannot judge whether there is non-autonomous gene
action between di¡erent cells within that tissue.
Mom1 fails to show one hallmark of a cell-autonomous
negative regulator of neoplasia: loss of heterozygosity
within tumours. Min-induced tumours in Mom1 hetero-
zygotes remain heterozygous over the Mom1 region (Dove
et al. 1994) and in particular for Pla2g2a (Gould et al.
1996b).This genetic behaviour of a non-autonomous nega-
tive regulator of neoplasia canbe classi¢ed as maintenance
of heterozygosity (MOH). This observation is consistent
with expression of the secretory phospholipase from the
Paneth cell (Gould & Dove 1997).
Finding that a secretory phospholipase can act as an
active resistance factor, controlling the size and multi-
plicity of Min-induced adenomas, indicates that in some
way lipid signalling positively regulates a biological
process that limits the adenoma. Conceivable candidate
biological processes include migration from the prolifera-
tive niche of the tumour, di¡erentiation into post-mitotic
derivatives, or position-dependent apoptosis. Super¢cially
at least, these possibilities are distinct from those that
underlie the e¡ects of mutations in the inducible cyclo-
oxygenase gene Cox2 (Oshima et al. 1996). Here, a loss of
function results in a strong reduction in adenoma size and
multiplicity, as if Cox2 were a positive growth regulator
involved in the metabolic maintenance of the adenoma
through prostaglandin biosynthesis.Thus, two contrasting
roles can be imagined for the e¡ects of lipid metabolism in
general on adenoma formation or maintenance. Perhaps,
the secretory phospholipase does not operate through
prostaglandin biosynthesis.
Does the study of Mom1and the secretory phospholipase
in the Min mouse bear on human colon cancer, familial or
sporadic? Several investigators have failed to ¢nd an asso-
ciation of the allelic status of the human homologue
PLA2G2A with the severity of familial colon cancer or the
risk for sporadic colon cancer. Furthermore, somatic muta-
tions in this gene have not yet been found in human colon
cancers (Riggins et al. 1995; Spirio et al. 1996; T omlinson et
al. 1996a,b). The failure to ¢nd mutations in tumour
material is explained if the e¡ects of the secretory
phospholipase are non-autonomous to the tumour. The
failure to ¢nd epidemiological associations between
familial disease severity and the allelic status of PLA2G2A
may re£ect the fact that severely a¡ected mutant alleles of
this gene have not yet been found in the human popula-
tion, in contrast to the frameshift allele of the sensitive
C57BL/6 mouse strain. Thus, the relevance of the
secretory phospholipase to human colon cancer is
unresolved.
As a general proposition, the di¤culties in identifying
quantitative modi¢er loci in the human may remain
largely insuperable if one works solely with human family
data and performs genomic scanning for association of
genotype and phenotype. Crucially, one is also not
con¢dent a priori that the phenotyping of the available
human families has the same objective quality as that of a
closed population of heterozygous congenic mice segre-
gating for a single genetic factor. The clinical diagnosis
may emphasize the status of the most advanced tumour
in an individual rather than the overall adenoma pheno-
type (seeT omlinson et al. 1996a). Further, the contribution
of environmental variation to the phenotypic variation in
human populations may overwhelm subtle quantitative
e¡ects of modifying alleles. Thus, in a genomic scan for
modifying alleles, the statistical power to map a genetic
modi¢er may be inadequate to overcome the environ-
mental variation and the imprecision of the phenotyping.
It would seem that the best available strategy is to test
speci¢c candidate loci for phenotypic e¡ect within the
available human families. One source for candidate loci is
the set of human homologues of any modi¢er loci identi-
¢ed for the cognate process in the mouse. However, one is
not assured that equally informative alleles are available in
the two species. T omlinson et al. (1996a,b) have found an
association of an index of disease severity in FAP families
with the 1p35^36 region in the human genome
surrounding the PLA2G2A locus, although, ironically, not
with alleles of the secretory phospholipase.
5. CONCLUDING REMARKS
An entre ¨ e into the study of the intestinal epithelium is
provided by the Min strain of the mouse, a familiar intest-
inal cancer model. Beyond identifying the highly
penetrant germline lesion that leads to this cancer, we
have been able to identify a modifying locus, Mom1, that
alters the expressivity of the Min mutation. The strain
AKR contains alleles that modify the phenotype even
further, yet retain the common theme: Apc function must
be attenuated or lost in intestinal adenomas. The Mom1
locus constitutes the beginning of an exploration of the
genetic network that impinges on Apc and intestinal
cancer. The general use of the ROSA26 cell lineage
marker permits analysis of the clonality of the neoplastic
transitions and the range of action of any genetic modi¢er.
The cellular interactions within epithelia re£ect a
network of genetic interactions.The cellular/genetic inter-
actions and the overall dynamics of the network can best
be approached by ¢nding single genetic di¡erences that
a¡ect the system, identifying the molecule involved and
then analysing the mode of action by chimerism and by
cellular biochemistry. The analysis of an entire system
will bring human genetics into a new level of dialogue
with the biology of the human, moving beyond the search
for `disease-causing genes'.
The geneticist's response to the challenge lodged by
Garrod in his valedictory 1927 lecture (table 1) is to start
with a population of individuals at high risk to a disease
and to ¢nd mutant alleles that either suppress or enhance
that disease. We believe that Mom1 has no strongly
detrimental e¡ects of its own, because the C57BL/6
mouse is healthy although homozygous for a frameshift
mutation in the secretory phospholipase. In the presence
of the Min mutation, however, the status of the Mom1
locus makes a signi¢cant di¡erence, apparently by
conferring active resistance. Modifying activity on a
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with only favourable e¡ects.
The APC/Apc gene is broadly expressed in the mammal.
Indeed, both human and mouse families heterozygous for
APC/Apc mutations develop extracolonic lesions, including
desmoid ¢bromas. The incidence of these extracolonic
lesions depends on speci¢c modi¢er loci. De¢ciency for
p53 greatly enhances desmoid formation in Min mice, but
has little e¡ect on the early stages of intestinal neoplasia
(R. B. Halberg and W. F. Dove, unpublished data). By
contrast, Mom1does not strongly a¡ect desmoid neoplasia.
Thus, the neoplastic phenotype of Min mice involves loci
secondary toApc that are speci¢c for particular tissues.
In pursuing the whole story of intestinal cancer with the
laboratory mouse, there are two major needs: (i) the
expansion of the search for modifying alleles; and (ii) the
development of in vitro systems of analysis that recapitulate
aspects of the processes that are relevant in vivo. Meeting
the ¢rst need will surely enhance meeting the second, as
each in vitro preparation from mutant material will
provide a substrate for the study of the single missing
substance. The successes in developing haematopoietic
cultures that show response to the Steel and W mutations
have provided a strong precedent for such a general in
vivo/in vitro strategy (Dexter 1986; Dexter & Allen 1992).
Over the coming decade, investigations of the intestinal
epithelium in vivo may develop a more direct line of
communication with manipulations in vitro.
It will be interesting to see whether experimental inves-
tigations will bring forward an understanding of the
apparent six-hit actuarial incidence curve for clinically
diagnosed colon cancer in the human. Beyond epide-
miology, experimental investigators will want to explore
which fundamental biological lessons can be conveyed
from the laboratory into the realms of prevention and
therapy.
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